Form 4: Inovio Pharmaceuticals CEO Reports Stock Transactions
SEC Form 4
CEO Jacqueline Elizabeth Shea reports acquisition and disposal of Inovio Pharmaceuticals stock and derivative securities related to vesting of restricted stock units and options.
Summary
- On February 26, 2025, Jacqueline Elizabeth Shea, CEO of Inovio Pharmaceuticals, reported transactions involving the company's stock.
- These transactions included the acquisition of 5,852 shares and 18,632 shares of common stock through the vesting of restricted stock units.
- Shea also disposed of 2,493 shares and 9,088 shares to cover tax obligations related to the vesting of these restricted stock units at a price of $1.98 per share.
- Additionally, Shea acquired 105,649 common stock options and 85,201 restricted stock units on February 27, 2025.
- Following these transactions, Shea directly owns 46,550 shares of common stock, 37,263 restricted stock units, and 105,649 common stock options.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by the CEO. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about ownership changes.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC when company insiders, like the CEO, trade in their company's stock. It provides transparency to investors about the transactions of key personnel.
Stakeholder Impact
- The transactions may have a minor impact on shareholders by slightly increasing the number of outstanding shares as restricted stock units vest.
Key Dates
| Date | Description |
|---|---|
| 02/26/2022 | Date of grant for 17,557 restricted stock units, vesting in three annual tranches. |
| 02/26/2023 | First vesting date for 5,852 shares of the restricted stock units granted on February 26, 2022. |
| 02/26/2024 | Second vesting date for 5,853 shares of the restricted stock units granted on February 26, 2022. |
| 02/28/2024 | Date of grant for 55,895 restricted stock units, vesting in three annual tranches. |
| 02/26/2025 | Date of transactions reported in the Form 4, including vesting of restricted stock units and tax withholding. |
| 02/27/2025 | Date of acquisition of 105,649 common stock options and 85,201 restricted stock units. |
| 02/27/2025 | First vesting date for 52,825 shares of the 105,649 options granted on February 27, 2025. |
| 02/26/2026 | Vesting date for 18,632 shares of the restricted stock units granted on February 28, 2024. |
| 02/26/2026 | Second vesting date for 28,401 shares of the 85,201 restricted stock units granted on February 27, 2025. |
| 02/26/2026 | Second vesting date for 52,824 shares of the 105,649 options granted on February 27, 2025. |
| 02/26/2027 | Vesting date for 18,631 shares of the restricted stock units granted on February 28, 2024. |
| 02/26/2027 | Third vesting date for 28,400 shares of the 85,201 restricted stock units granted on February 27, 2025. |
| 02/26/2028 | Final vesting date for 28,400 shares of the 85,201 restricted stock units granted on February 27, 2025. |
| 02/27/2035 | Expiration date for the 105,649 common stock options granted on February 27, 2025. |
| 02/28/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.